GEN Genetic Engineering & Biotechnology News - Metabolon says that its Precision Metabolomics™ platform can improve quality control, data curation, and knowledge building. According to William LeFew, PhD, Metabolon’s director of data science, the company uses machine learning to automate routine tasks and teachable processes so its scientists can focus their efforts on the challenges that most require their expertise.
“We are honored to partner with NIAID and Metabolon in this effort to define how the human response to SARS-CoV-2 correlates to COVID severity and outcome. Metabolic features of the immune responses are increasingly recognized as pivotal to disease and health, and we are fortunate to have Metabolon’s excellent team by our side as we undertake this critical work.” – Dr. Ofer Levy, Director of the Precision Vaccines Program (PVP) at Boston Children’s Hospital
New and existing investors contributed to biotech’s largest ever capital raise; company also announced appointment of Robert A. Cascella, Chief Business Leader, Precision Diagnostics, and Executive Vice President of Phillips, as one of three independent members of the Metabolon Board of Directors.
January 20th 10:00 am EDT/16:00 CEST Successful drug development hinges on multimillion-dollar decisions about the mechanism of action, safety, dosage,...
Visit us at booth 610
Connect with 2000+ global scientists, engineers and executives working across the entire spectrum of biopharmaceutical development and production.
IGES is the International Genetic Epidemiology Society, a scientific society concerned with “the study of genetic components in complex biological phenomena” according to James V. Neel, the founding President of the Society. The successful mapping of the human genome will greatly facilitate the study of health and disease in a manner that integrates both host and environmental factors.
Join Metabolon’s Patricia Sheridan, Ph.D., Senior Study Director, Discovery & Translational Sciences, for a conversation with Dr. Heath on May 27th at 11:00 am EDT/13:00 CEST. They will be discussing some of the current work that ISB is doing to explore COVID-19 infections and how metabolomics can be used to understand the pathophysiology of the infection.
Enlighten your research,
accelerate your discovery.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
Leveraging Machine Learning to Advance Precision Medicine
National Institute of Allergy and Infectious Disease (NIAID) Selects Metabolon, Inc. for COVID-19 Study
Metabolon, Inc. Announces $72 Million in Debt and Equity Financing to Accelerate Advancements in Precision Medicine and Innovative Drug Development Technologies